Healthcare News 12

• "Ask Not for Whom the Bell Tolls...It Tolls for Medicare"
• "New Class" is more likely the new "Standard of Care"
• A better vaccine- so what is there to say
• A Big Win for Glaxo
• A Diamond in the Rough
• A limited but bright future
• A New Algorithm Will be Needed to Calculate Market Sharee
• A new class of drugs - growth in sale and hope for cure in human immune system
• A new class of drugs - growth in sale and hope for cure in human immune system
• A new drug that would change the way we treat Atrial Fibrillation!
• A New Non-stimulant Approach to ADHD?
• A Non Epo Product for Anemia of Chemotherapy? Will this dog hunt?
• A plug to treat AFS with local antibiotics.
• A red herring or a decoy? AVONTEC in asthma
• A relief, albeit a temporary one
• A Very Promising Approach to ADHD but Initial Claims and Monitoring Will Be Important in Success
• Abbot's potentially interesting avenue of approach to adult ADHD
• Abbott Targets Adult ADHD with Nicotinic Drug, Shows Strong CNS Pipeline
• Abbott's ABT-089 --Much More than a Treatment for ADHD
• Abilify (Otsuka Pharm and Bristol Myers Squibb - BMY): Will Kids Benefit - or Just BMY
• Aclasta has implications for a large cohort of healthcare patients
• Aclasta, or How to Make a Market Where There is None
• Adulterated Chinese Heparin, It Happens.
• Advance in Small Cell Lung Cancer (SCLC)?
• Advantages of SenoRx Contura over Mammosite Breast Brachytherapy system.
• AGI-1067 May Address More than the Blood Sugar
• Alcon (ACL) reports Promising Results for Unique Glaucoma Medication.
• Alimta (Lilly): Approved as First Line Agent in Europe for Non Squamous Cell Lung Ca!!!
• Alimta (Lilly): YES!!!!
• Aliskiren the good, bad and the quest.
• AllScripts - Misys Merger Investment analysis
• Alynlam (Nasdaq: ALNY) Brings the RNA Messenger to the Messenger RNA
• Amgen Stock Set to Take a Fall!
• Amgen, Well at least they have Aranesp. (Whoops!)
• Amplimed (?) anything for pancreatic ca would be worthwile.
• An RNAi drug works In people - is this relevant to cure neurodegenrative disease?
• An unmet need still unmet, tough luck for Pfizer
• AN2728 phase 2a results encouraging.
• Analysis of Wal-Mart's Generics Plan
• Anemia Drugs Have Been Abused for Profit!
• Announcing the 1-Day Acuvue TruEye a New Silicone Hydrogel Contact Lens
• Another attack to Merck
• Another Casualty in Antidepressant Development
• Another Glinide: Where's the Beef?
• Another Good Agent for the Pediatric Age Group
• Another nail in the coffin
• Another New FDA Indication For Abilify
• Another player in the market
• Another reason to use Lipitor
• Anti=inflammatory agents not protective for Adult dementia
• Antigenics gain approval for autologous vaccine in Russia
• Antisoma drug combines novel immunotherapy agent with fused targeting antibody
• Antisoma's ASA404: Another Anti-Angiogenesis Agent to Watch
• Apocalypse Now: Physicians and Insurers Agree on Performance Measurement Principles
• Are all inducements bad?
• Are physicians who represent plaintiffs any less biased than researchers working with a pharmaceutical company
• As an experienced injector (have injected all fillers including silicone), I have evaluated all the injection materials used and there are concerns with non-medical grade filler materials.
• ASA404 approach in treating lung cancer
• ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
• Aspect Medical Systems in the Spotlight- The Bis Monitor, Medical Need and The Capital Markets
• AstraZeneca's (AZ) IRESSA still alive in Europe.....? There is life after failure in the US.
• AtheroGenics' AGI-1067 Shows Some Promise, But There Are Still Questions
• Avastin (Genentech) a double edged sword?
• Bad press - bad news
• Bad show for Big Pharma
• Base Product in Baxter's Heparin Came from China!
• Belive it when you see it
• Better alternative for short term pain management
• Beware the Unlicensed Practitioner!
• Bexarotene (Ligand) It's SPIRIT is alive in a subset of lung cancer patients.
• Big CATTs and catching pharma by the tail.
• Big opportunity for Glaxo
• Big Pharma Losing Control
• Big Pharma R&D shrinks as small Pharma and Biotechs Rise to Fill the Gap in R&D
• Big Pharma's future
• Big Premium in the McKesson–McQueary Deal
• Bigger is not always better
• Bigger markets or validation of current use?
• Biosimilar " Neukine" will add to Amgen woes and is just tip of the iceberg!!!
• BioSimilar G-CSF Might be Coming: How Will it Stack up to Neupogen?
• Biosimilars from India
• BITE antibodies for solid tumors: Still more bark than bite!!!
• BiTE shows more promise than most but no fianlity yet
• Black eye on pharma in general
• Brain Cancer: Several new treatment strategies with an expected boost from the recent Senator Kennedy diagnosis
• BrainCells Novel Antidepressant: Targeting Neurogenesis but not Serotonin?
• BRCA Mutations less risky than thought
• bribes and bad apples
• Broader implications to Novartises Announcement
• bubbles always BURST
• Bucking the barriers
• Business Transformation at Wyeth
• CA Sets More Realistic Pedigree Deadline, but Timeline Still Uncertain
• California Delays Drug Tracking Law to 2011
• Can Glaxo’s Affymetrix Microarray Predict Who Will Benefit from its MAGE-A3 Immunotherapy?
• Can I eat until my IQ drops to 120.......?
• Can NOV-002 from Novelos Therapeutics Break into Therapy for Breast, Lung,or Ovarian Cancers?
• Cardinal Health Apologizes To Customers
• Cardiovascular Risk Assessment
• Carfilzomib: Efficacy may be best in hematological malignancies
• Caught between a rock and a hard place? not really
• Cause and effect? Or just temporal association?
• Celgene's Revlimid: A new Rituximab?? but hardly a new Gleevec!!!
• Cerberus May Be Looking to Sell Talecris Biotherapeutics
• Change is coming get on board or lose
• China-not your low cost center any longer
• China's Full Scale Entry into the Generics Industry
• Chinese generics is nothing new
• Chinese generics: Low prices bu qulaity reputation will favor India
• Chinese Generics?? You must be kidding!
• Cimzia in Crohn's Disease
• Clinical Analysis of GSK's Rotarix important to success of vaccine
• Clinical trial for AEG33773 for the treatment of painful diabetic neuropathy begins with human population group
• CMS Raises the Kimono on Medicare Part D Claims to Improve Patient Safety
• Colon Cancer Company Seeks Strategic Business Alternatives
• Colorectal Cancer Agreement Between Quest and Epigenomics
• Comments on Novartis Menveo vaccine
• Co-Morbidities Associated with Psoriasis
• Competition for the statin/niacin combo
• Confirmation Trial is Needed
• Contaminated solutions or sterile, your choice.
• Continuing Genentech's Herceptin - Confirming What We Suspected
• Controlled Substance Diversion
• Cooper Vision needs Avaira to be successful to maintain it's status in the Contact Lens Industry
• CooperVision enters US market with Avaira™ two-week silicone hydrogel contact lenses
• COPAXONE from the START of MS
• Co-Payments for Expensive Drugs Soar: Does Pharma really want governmental controls?
• Corcept Therapeutics Takes Yet Another Shot at Psychotic Depression
• Cosmetic Dentistry is Necessary in Any Economy
• CT scanning to detect early lung cancers? Flawed due to ethical concerns
• CTLA4 Blockade in Melanoma: Where Next?
• Cubicin not tainted but delivery device.
• Cubist's Antibiotic Cubicin is Tainted: A Mess Not of Their Doing? Maybe, Maybe Not.
• Curis, Inc (CRIS, NASDAQ) & Genentech in partnership Re: a hedgehog antagonist in colon cancer
• Current and future standing of tecturna
• Current trends with Venture Capital Funds and IPO's
• Data is Not Information
• Datascope Benefits from Sale of Patient Monitoring Business
• Decreased DEXA reimbursement implications
• Depressing Math: More R&D Money Spent Equals Fewer Novel Treatments, Higher Prices, and Investing Outside the Company
• diabetic neuropathy commonest presentation in long standing diabetic
• Difficult, but not imposible, trial to complete
• Direct to Consumer Marketing Fiasco
• Dissapointing results
• Diversion dilema will only continue
• DNAi - early stage excitement
• Do not forget the cost of supplying from China
• does straterra work?
• DOJ Joining Suit against OH MDs and Hospital
• Don't Get Sick After Hours: The Crisis to Improve Patient Care
• Doubts About LASIK
• Drugs May Help - Studies With Patient Education Needed
• Early Alarms bells missed here, Outsourcing Strategies at Catastrophic Risk
• Education is over rated regarding pharmaceuticals
• efficacy vs safety
• EHR is way too expensivce and unaffordable for the majority of Physicians
• Electronic Health Record Company Mergers--Is this the First Domino?
• Eli Lilly is on the right track with gamma secretase inhibiors
• Erbitux (ImClone):1 month and <10% additional survival in lung cancer. Not very impressive!
• Erbitux and Lung cancer
• Erbitux did not add to response rates in newly diagnosed in NSCLC
• Erbitux: Alot remains to be determined re: its place in NSCLCA therapy
• Europe in advance!
• European Medicines Agency (EMEA) has followed Committee for Medicinal Products for Human Use (CHMP) to reject Cimzia® (certolizumab pegol)
• Eurpean phase III study for Huntingdon disease- clinical efficacy for ACR16
• Expect great benefits from GlaxoSmithKline / AVANT Immunotherapeutics ROTARIX vaccine
• Expect speeder FDA reviews in a year maybe.
• Experts in the oil industry have stated for the past year that $4 / gal. gas will initiate oil and energy conservation.
• Ex-PRESS Shunt (Optonol) making Strides for Surgical Managment of Glaucoma
• FDA Analysis of Singulair- Wait until the evidence is in.
• FDA approval of strattera in kids should be good news for Lilly
• FDA Approves Molecular Respiratory Virus Panels
• FDA Explodes ZymoGenetics' Recothrom Safety Argument
• FDA Fees Must Be Increased to Fund Inspection of Chinese Products.
• FDA Gives ISIS (Nasdaq: ISIS) a Gift (?) in its Efforts to Develop Mipomersen
• FDA, Baxter and SPL are all responsible for contaminated Chinese-processed Heparin
• FDA: Chinese Manufacturer of Tainted Heparin Involved in Fraud.
• Feds Now Won't Pay for 9 Additional Conditions in Medicare Patients Starting in October
• ferumoxytol Any advantage over current IV iron
• Fillers
• First OTC Diagnostic Testing, then Home-based Auto-surgery?
• Fixed doage of metoprolol utilized
• Flamel Technologies and Interferon Alpha XL
• Galaxo's Win is a Win for The Industry
• Genentech still has a lucrative drug pipeline , but may not meet zelous estimates.
• Genentech, Schering-Plough,,Avant Immunotherapeutics. & Pfizer all helping with "brain cancer" therapy.
• Genentech/Avastin: Drp in sales?? Be patient!
• Genentech’s Avastin Appears Safe in Early Colon Cancer
• Genetic drivers of lung cancer risk identified.
• Genetic Testing Will Move to Mainstream Acceptance
• Genomics are coming! Are we ready?
• Genomics!!! I told you so......
• Giving Credit Where Credit's Due for Hospital Tech Spending
• Glatiramer failure in ALS a multicentric andomized trial supportd by TEVA
• Glaxo Decision Moves Drug Development Forward Again
• Glaxo vs Merck
• Glaxo's Promacta Hits a Snag with the FDA
• Global Cancer Market: room for further growth!
• Good for Alcon, little effect on the patient, slight decrease in competition.
• Good move
• Good news -but will Medicare and others cover it?
• Good news for Obesity - Taranabant shows significant weight loss
• Good Prospect- but how much will it cost?
• Good Summary of Current Practices
• Government Cuts in Funding for DXA in Physicians' Offices May Lead to Difficulties for Rural Patients
• Growth of biologics
• GSK gets there first (for a change)
• GSK has a monoclonal antibody (Mepolizumab) that can treat patients with "hypereosinophilia.)
• GSK joining the RNA wave
• GSK Will Always Win Price Competitions
• GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)
• Head to Head Comparisons will Help Patients but Hurt Profits
• health care costs
• Health Plans Cannot Control Costs Any More Than Physicians Can
• Hedgehog pathwa drugs and chemotherapy
• Hefty price but promising potential
• Hematide: a long acting ESA with more potential in chronic renal failure than in chemotherapy induced anemia.
• Herpes Labialis Medicaments
• Hospitalized Children at 450% Greater Risk of Harmful Medication Errors than Thought
• How Cancer Drug Affects Kidneys
• How to Make Two Hospitals as Good as One
• Huntington's Disease: Muting the Mutation - Let's Not Forget Alnylam (ALNY)
• Hydrocodone ER Could be Welcome Addition to Pain Arsenal
• Hype and hope for another cancer vaccine
• I find it hard to believe...
• I lean toward "Bust"
• i WAS ONE OF THE PHYSICIANS THAT HELPED TO LAUNCH EXUBERA. I WAS VERY EXCITED ABOUT THE UTILITY OF INHALED INSULIN IN THE RELUCTANT TO INJECT AND FEEL THAT ANY NEW INHALED PRODUCT CAN BE HUGE IN THE INSULIN MARKET.
• IL-13 in asthma
• ImClone: Does Morgan Stanley (MS) know something we don't??
• ImClone: One study shot down. The other??
• Immunoconjugates Are Better in Theory Than Practice
• Implementing Cost Controls Over Runaway Health Benefit Expenses
• Implications for Astigmatism
• Implications of mechanism's of action? Who cares if it works!
• Important New Data for Children and Adolescents
• Impressive Opportunity Treatment for Prevention of Pandemic Flu
• Impressive results in competitive environment
• Improved User Friendliness Is the Key
• Improving anesthetic/surgical outcomes- the role of pharmacoprophylaxis
• In Rotateq v. Rotarix, cost is only 1 issue
• Income Streams and Salmon
• Industry leaders need to work with the US Patent and Trademark office to keep US patents strong
• Injectable glaucoma drug vs. patient compliance
• Injections by non medical personal can be dangerous
• Innovative therapies for cancer by Immunomedics - a promising ttherapeutic intervention
• Insurers and Pharmacy Benefit Management Companies Will Continue Covering Vytorin
• Insurers Should be the First Line of Defense Against Vytorin
• Interesting finding but not what I hear from practicing Rheumatologists.
• Interesting Transaction
• Interesting, but be careful with the interpretation
• Intuit marketing success trumped by data
• Investment opportunities in cosmetic dentistry
• Investors Have Overreacted: The Use of BIS Devices to Monitor the Depth of Anesthesia Will Not Be Affected by One Negative Article
• Is LASIK the issue or is choosing the right refractive surgery for the right patient the real issue?
• Is Novartis finally conceding that MF59 is a bad flu adjuvant?
• Is the cost of new agents validation justifies the potential high cost in the clinical practice?
• It is time to control the price of brand-name medication
• It Remains to Be Seen
• Just a Matter of Time
• Laparoscopic Prostatectomy: Long-term Data Raises Questions
• Laparoscopic Surgical IS NOT to blame for surgeon outcomes
• Laser Refractive Surgery is Here to Stay
• LASIK IS AN EXCELLENT PROCEDURE FOR THE APPROPRIATE CANDIDATES
• Lead In Toys/Contaminated Heparin vs Lower Cost Drugs!
• Lenalidomide is on a surge
• Lessons Learned the Hard Way: Dangers of Using Non-Licensed Cosmetic Injectors
• Let the Rotavirus battle begin!
• Lexicon's drug for RA
• License Agreement is a feather in the cap for Airmid but is a long shot to deliver an approvable drug
• Licensure and Training
• Lily's impact likely minimal
• Limited Clinical Utility Doesn't Necessarily Stop a Test from Being Used
• Limited Clinical Utility Doesn't Necessarily Stop a Test from Being Used
• LIPITOR is the most powerful statin in cardiovascular area
• LONG TERM ADIICTION CENTER MEDICAL DIRECTOR COMMENTS ON USE OF NARCOTIC ANALGESICS.
• Long term use of Allergan's Botox does not decrease efficacy
• Long-Term Symbicort Use in persistent Asthma - is it a solution for young children with asthma?
• looking to the future
• Lung cancer vaccination: a kinder, gentler (sic) therapy?? We will see..
• manufacturing not up to GMP
• Many Interleukins in the pipeline, when will they all come together?
• Market implication of merger
• May be jumping into phase II too soon
• McKesson Avoids Major DEA Impact
• McKesson Gets Out of Pharmacy Outsourcing
• Medicaid Health Plans Under the Microscope - Amerigroup Sued by District of Columbia
• Medicare: heading toward a crisis
• merck does the work
• Metabolic syndrome is a misnomer and cannot be measured by surrogate measurements accurately
• Metabolic syndrome is not an independent cause of cardivascular events: implications for drug development and use
• Might Be a Lesson Here....
• Millennium purchase may open up avenues for more sales??
• Mindray Completes Acquisition of Datascope's Patient Monitoring Business
• Mipomersen will make it to market but with limited market share
• Misys replaces IDX
• Molecular Diagnostics May Revive Failed Drugs
• More agents for neuropathic pain
• More bad news for Merck
• More medications for migraine are always in need
• More oversight to foil bribes is wishful thinking
• More potential developments in chronic lymphatic leukemia (CLL) therapy!
• More Progress on the Vaccine Front
• More R & D spending are needed
• More Trouble for Cardinal Health
• NABP Exposes Fake Candian Online Pharmacies
• Naproxen and Celecoxib fail to improve cognitive functions for patients with neurodegenerative disease
• National healthcare? Better find a new pool of physicians
• National Supply Chain Security Standards Will Benefit Everyone
• Neuronal nicotinic receptor agonists potential breakthrough for ADHD research
• Neuropathic diabetic pain is increasing over the world mainly in wester countries to date many drugs allowed only a modest pain relief , this new drug has a higher potential in limiting pain and depression post-pain, the way of administration and tolerance is better that current drugs on the market , this drug may allow a de crease of depression related to pain because it may target a specific centralnervous systel receptor involving in depression process
• New Agents Needed for Therapy of Neuropathy in Cancer Patients- Is AL-309 the Agent?
• New Drug Discovery Pact with GVK BIO allows Wyeth to increase its Biotechnical Capacity.
• New era for SEROQUEL® (quetiapine fumarate) - approval from the FDA
• New kind of monoclonal antibodies mean better results?
• new osteoporisis medication by AMGEN; Wall Street Journal Article
• New Proteosome Inhibitor Carfilzomib Ready for Another Phase II Study
• New targets mean better clinical results?
• New Therapy for Hormone Refractory Prostate CA. Maybe!!!
• New Tool Pain Managemet
• NNRs: A Novel direction?
• No One is Paying $30K For One More Month
• No side-effects for Lorcaserin after 12 months of use - boosting share market
• Non small cell lung cancer has little to be excited about
• Non-chemotherapy "clever" anti-cancer agents are actually safer?
• Not a Huge Advantage Over the Current Product
• Not Likely a Big Deal
• Not surprising
• Not the Utility One Might Expect
• Novartis (Tekturna) Effective BP med but is it worth the cost?
• Novartis and Multiple Sclerosis: A Major Commitment
• Novartis grabs a winner
• Novartis initiated, positive in randomized phase II trial- I think they (we) may have something!
• Novartis Needs To Be Nimbler Than Larger Rivals
• Novel immunotherapy for prostate cancer
• Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke
• NSAIDS and Alzheimers
• Obvious answer - wrong question - NO IMPACT on prescribing
• obviously works better
• OK, now that we know why how can we prevent the reactions to increase utilization of BMS & Imclone's Erbitux?
• Oncophage approval in Russia: Following Sutton's Rule!!!
• Oncophage(R) : Let's wait until the results are duplicated in Costa Rica.......
• Oral PBI-1402 from ProMetic Life Sciences Inc. Might Have the Potential to Fill the Void Left by the EPO Stimulating Agents
• OTC Diagnostics Could Yield High Growth
• Ovarian Cancer
• Overuse of Lupron & Zoladex in "early" Prostate Carcinoma?
• Paying to play catch-up
• PERISCOPE Makes Sense
• Personalized Medicine
• Pfizer adds to the list of late stage melanoma drug failures
• Pfizer Anti-CTLA4 antibody trial for melanoma stopped for futility
• Pfizer should know better than to intentionally act against it's own long term interest losing the trust of MD's and people.
• Pfizer's Melanoma Treatment Setback Has Bigger Implications
• Phase 3 without Phases 1 and 2
• Phase II Data are Intriguing for Boehringer Ingelheim's BIBF 1120 Pill in Pts with Advanced Lung Cancer
• Phase III data for Advexin - the devil is in the details
• Physician owned hospitals. Beneficial to whom? Certainly not the patient!!!
• Physician Ranking Systems Going Mainstream With National Focus
• PI-3-kinase inhibitors are the next class of anti-cancer drugs
• Piramed, GDC-0941. PI3K inhibition by GDC-941 as a promising tool to hamper a crucial tumorigenic signaling
• Pitfalls in Lupus
• POISE shows high-dose beta blockers reduce heart attacks but cause more harm than good overall.
• Police Department Focuses on Getting Officers to Lose Weight
• Possible wave of the future---or the present
• Post laser prostate laparascopic TURP problems
• potential innovation within anti-CD20 therapy
• Potential new medication in the fight against AD
• Practise with evidence based medicine
• Prevention is better than cure - Medivir's successful phase III clinical trial for Lipsovir(R)
• Price Controls are Not the Solution to the Annual Increases in Pharmaceutical Costs
• Problems for DaVinci
• Production techniques cause unsafe heparin to be spread through the world resulting in mortality
• Promising results for tekturna
• Promising results from clinical trial for Bosatria - a success for GlaxoSmithKline
• Prospective drug for Alzheimer's disease - Phase III cinical trial from Lilly
• Protection of the heart compromises systemic circulation and, therefore, brain perfusion: POISE trial
• Proteosome Inhibition with Carfilzomib is Promising Therapeutic Avenue
• Psoriasis associated with comorbidities- Is this to be expected?
• Psoriasis can lead to cardiovascular disease, depression and cancer - an interesting overview
• R&D Spending is critical to the branded and generic markets
• Relationships Between Manufacturers and Physicians will be More Closely Scrutinized, not Just in Orthopedics
• Relative ineffectiveness of chemotherapy for NSCLC
• Reliable diagnosis of RSV infection could be a major improvment for immunecompromises patients
• Results are good for a press release - the real implication are questionable
• results teach us something?
• Reverse Payments for PHRMA smell fishy
• Revlimid (Celgene) in CLL- not a bad addition in our therapeutic algorithm
• Revlimid in non-myeloma malignancies? A review article? It's time is coming!
• Ricin Vaccine Market Relies on Threat of Terror
• Risks when Politicians Tackle Supply Chain Security
• Rituxan ( Vitamin R ): Let's not panic!!
• Rituxan and Lupus: Is there Hope for the Nephritis Study?
• Robotic Prostatectomy ?Too soon to tell?
• Roche's Xeloda to gain more use in frontline treatment of m-CRC
• Rotarix will all come down to cost
• ROTARIX(R) Rotavirus Vaccine Will Give Pediatricians Another Vaccination Option
• Rounding Out Lilly's Diabetes Armamentarium
• safety concern with chinese drugs
• Second anda half line drug
• Seeking formal approval for Ramelteon use in Japan- is this a beginning for Ramelteon's global market?
• Serious Skin Reactions with TNF antagonists
• Should not be a driving force
• Should we use cetuximab in all NSCLC patients?
• Sickle Cell Anemia: Does Icagen, Inc have an answer in senicapoc (ICA-17043)?
• Siemens and Labcorp form Alliance
• Singulair increases risk of Suicide? Don't just poo-poo the possibility
• Singulair suicide story won't kill Merck
• Slim Chance?!
• Slowly but surely, Primary Care gets the message about preventing asthma
• So it begins...
• So Maybe there wll be a National Health Information Network (NHIN) after All
• So much for non-invasive surgery in prostate cancer
• Sounds impressive. Mechanism key to barrier to competition
• Squeaking hips show risk of early adopting
• Startling New Evidence Suggests IVIg May Help Alzheimer's Patients
• Stay Away From Liquid Silicone Injections.
• Stem Cell Reseach - A step in the right direction
• Stem cells for Mulitple Sclerosis
• STEMI patients do better with clot aspiration prior to stenting
• Still too early to tell
• Straight Talk From Cardinal Health’s George Barrett
• Studies favor new Amgen drug for osteoporosis - will the patients like to inject denosumab?
• Study of Breast Cancer Risk May Impact Myriad Genetics
• Supplements Proactive
• Sure, and let's buy them all a pony, too!
• Surprising Growth by Independent Pharmacies
• Sustained-release Hydrocodone - so what?
• Sustained-release opioids
• Symbicort for children
• T cell reconstitution after transplant
• Tainted Heparin Will Mean More Scrutiny of Drug Manufacturers
• Tapentadol: The New Ultram?
• Taranabant directions: To gain or to Failure
• Taranabant Drections: To Success or to Failure?
• Taranabant--To Be or Not To Be
• Tekturan losers blood pressure and proteinuria simultaneously
• Tekturna scripts
• TEVA CAN BE FIRST TO MARKET, and IMPROVED SUPPLY DISTRIBUTION
• Thalidomide (Celgene) use to be liberalized in Europe
• The AMP Pharmacy Reimbursement Saga Drags On
• The answer is yes.
• The benefits of using oral HRT can not outweigh fatal risks
• The DOJ and the FTC rarely join antitrust suits unless there is the likelihood of merit
• The Feds Get Personal with your Medical Records
• The gods giveth and then takith away- Go figure.....
• The Human Genome will promote genetic counciling chaos and misinformation
• The Next Big Thing in Cataract and Lens Based Surgery: The Light Adjustable Lens (LAL)
• The pros and cons of Strattera driving marketing
• The real money is off-label
• The Required Success Factorsfor China to Muscle into Genetic Industry
• The Right Decision
• The role of immune system in the era of biological anti-cancer agents
• The Vioxx Problem
• Therapeutic intervention to treat psychotic depression - clinical trials to evaluate CORLUX continues
• This article may change atopic dermatitis treatment by pediatricians
• This should be a significant advance.
• Thrombus Aspiration in Acute MI
• Thrombus aspiration with the Medtronic Export: the new standard PCI approach?
• TNF worked in dogs but not humans
• Too Early to Draw Conclusions Yet on Vargatef
• Too early to tell
• Too much of a "good' thing
• Transgene's TG4010 Vaccine for Lung Ca - Add it to the List...
• TREANDA for CLL could be a winner
• Troubled Times on the Lipid-Lowering Drugs Market
• Trovax for renal cell carcinoma: not much potential
• Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
• TRU-015 and SBI-087 both trubion's product both strong products with Different MOA , B cell depletion.
• Truth vs. Profits
• Unlicensed person injecting silicone unlikely to impact filler market
• Ustekinumab shows promise
• VIA 2291 reduce inflamamtion in atherosclerotic plaque , a new target in prevention
• Visudyne teraphy may play a new role in AMD treatment
• Vytorin resolution not soon
• Waste not Want not: Will this Ever Apply to U.S. Healthcare?
• Well at least they have Procrit (Whoops!)
• Well Designed Study Fails to Confirm a role for Anti-inflammatory Medications in preventing Alzheimer's disease - Hardly Surprising
• Wellpoint restricting epo products. Am I surprised?? No!!
• What a bunch of horse crap.
• What is the optimal tumor stage for vaccination?
• What strategy Pfizer will take (advanced Melanoma fails to give positive results) ?
• Where is the profit in Healthcare Packaging?
• Who benefits from the court-mandated halt to the clinical laboratory competitive bidding demonstration project?
• Who to Blame for Waste in the Medical Industry? Who's on First?
• Whole Health Care Systems - Open Communication and Education
• Why in pancreatic cancer???
• Why will Glatiramer work for ALS
• Why Xeloda can't eliminate 5FU
• Will bone drug help Amgen?
• Will clearly change practice
• Will have a niche
• Will Not Meaningfully Change Prescribing Patterns
• Will Strattera be around in 3 years?
• Will The Avaira Take Market Share From Oaysis?
• WSJ Hypes McKesson Buyout (Again)
• Wyeth's Job cuts are due to Generic erosion of their marketed products.
• XELOX=FOLFOX! Score one for Roche!
• Xenophobia and Valid Fears: Chinese comestibles and US Health
• You can freeze "leftover" TPA and save money. No need to by CathFlo or Actilyse.
• You Don't Have to Fear Discrimination Based on Your Genes
• You get what you pay for